Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
STAR protocols2026ResearchNon-viral Gene Delivery

Protocol for the production of high-yielded research-grade AAV vectors in transiently transfected HEK293T cells

Duke L, Kantor BDOI 10.1016/j.xpro.2026.104938
Read the original on PubMed ↗

Summary

Adeno-associated vector is a platform of choice for delivering genome-editing toolkits, due to its transient and robust expression. Here, we present a protocol for viral production for in vivo use. We describe steps for transfecting producer cells, harvesting virus, and purifying/concentrating viral particles. We then detail procedures for estimating viral titers. This protocol ensures high viral yields and transduction competency and is scalable to meet user-customized production needs. For complete details on the use of this protocol, please refer to Kantor et al. 1 .

Keywords

CRISPRCell BiologyCell cultureCell-based AssaysGeneticsGenomicsMolecular BiologyProtein Biochemistry

Adeno-associated vector is a platform of choice for delivering genome-editing toolkits, due to its transient and robust expression. Here, we present a protocol for viral production for in vivo use. We describe steps for transfecting producer cells, harvesting virus, and purifying/concentrating viral particles. We then detail procedures for estimating viral titers. This protocol ensures high viral yields and transduction competency and is scalable to meet user-customized production needs. For complete details on the use of this protocol, please refer to Kantor et al. 1 .

Abstract from PubMed (PMID 43007872). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.

Related articles

RSC advances

The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery

Nature communications

Interpretable AI-guided discovery of degradable ionizable lipids with enhanced hepatic mRNA delivery in vivo

Advanced pharmaceutical bulletin

PLGA Based "Lipid-Polymer Hybrid Nanoparticles": A Convergent Platform of Active and Targeted Drug Delivery

← Back to all articles

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Protocol for the production of high-yielded research-grade AAV vectors in transiently transfected HEK293T cells | Brilliant Blue Biosciences